Scientists dive deep into Epcoritamab's effects on Hard-to-Treat blood cancers

NCT ID NCT06676033

Ongoing Knowledge-focused Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study looks at blood, lymph node, and bone marrow samples from 5 people with chronic lymphocytic leukemia or Richter syndrome who are receiving the drug epcoritamab. Researchers want to understand how the drug changes immune cells and tumor cells over time. The goal is to learn more about how this type of immunotherapy works, which could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epcoritamab
What this could lead to: If successful, this study could reveal how epcoritamab attacks cancer cells, helping to improve future treatments for CLL and Richter syndrome.
What could go wrong: This is a very small, early-phase study with only 5 participants, focused on lab analysis rather than direct treatment outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, CHRONIC LYMPHOCYTIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, CHRONIC LYMPHOCYTIC RICHTER SYNDROME

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.